ImmuneOncia, WuXi Biologics partner for bispecific antibody development
ImmuneOncia will use WuXi Biologics’ services in bioassay development, cell line development, cell culture development.
China
Latest in
China
China’s latest NRDL update continues to exclude foreign PD-1 inhibitors, favours rare disease drugs
China’s much-anticipated update of its National Reimbursement Drug List (NRDL) presents a mixed bag for overseas pharma. Overall, there were…
By
China approves Brii Bio’s antibody combination therapy for Covid-19
The amubarvimab/romlusevimab is approved currently for adults and under conditional approval for adolescents aged 12 to 17 years.
Chinese bio/pharma oncology IPOs metastasise
The number of IPO deals in China has grown consistently over the last five years where oncology has remained the…
By
Chinese review designations lag behind US and EU
Chinese review designations currently lag behind the US and the EU in terms of the number of designations awarded.
By
Link Health to obtain global rights for Bone Therapeutics’ cell therapy
The new agreement is in addition to the deal entered last year to develop and market ALLOB.
Chinese infectious disease venture financing receives a booster from Covid-19
The impact of the Covid-19 pandemic has raised the importance of funding drug development for the treatment of infectious diseases.
By
Accelerated approval designations decelerate compared to other designations in China
Only two Accelerated Approval designations have been awarded in China since 2015, despite an increase in other drug designations.
By